semaglutide news november 28 2025 FDA Approves to Reduce Kidney Disease, Cardiovascular Death Risk in Adults With Type 2 Diabetes, Chronic Kidney Disease Insurance coverage just changed for

Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis-a randomized, multicentre, placebo-controlled study

Tang, G

Given the surging popularity of obesity management drugs in recent years, the FDA put out a warning singling out compounded GLP-1s, calling them risky for patients. The agency said it had received hundreds of reports of adverse events linked to compounded semaglutide (392) and tirzepatide (215) as of Nov

p = 0.52 for interaction between subjects with established CVD vs risk factors only) (Fig

Your healthcare provider may adjust your dose gradually, but the weekly injection schedule remains consistent